PL3927347T3 - Kombinacja leków do stosowania w sposobie leczenia raka wątroby - Google Patents

Kombinacja leków do stosowania w sposobie leczenia raka wątroby

Info

Publication number
PL3927347T3
PL3927347T3 PL20759361.7T PL20759361T PL3927347T3 PL 3927347 T3 PL3927347 T3 PL 3927347T3 PL 20759361 T PL20759361 T PL 20759361T PL 3927347 T3 PL3927347 T3 PL 3927347T3
Authority
PL
Poland
Prior art keywords
liver cancer
drug combination
treating liver
treating
drug
Prior art date
Application number
PL20759361.7T
Other languages
English (en)
Inventor
Mark ALBERTELLA
Original Assignee
Medivir Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Aktiebolag filed Critical Medivir Aktiebolag
Publication of PL3927347T3 publication Critical patent/PL3927347T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20759361.7T 2019-02-18 2020-02-17 Kombinacja leków do stosowania w sposobie leczenia raka wątroby PL3927347T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1950202 2019-02-18
PCT/SE2020/050175 WO2020171757A1 (en) 2019-02-18 2020-02-17 Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody

Publications (1)

Publication Number Publication Date
PL3927347T3 true PL3927347T3 (pl) 2024-05-06

Family

ID=72143660

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20759361.7T PL3927347T3 (pl) 2019-02-18 2020-02-17 Kombinacja leków do stosowania w sposobie leczenia raka wątroby

Country Status (12)

Country Link
US (1) US20220117983A1 (pl)
EP (1) EP3927347B1 (pl)
KR (1) KR20210130768A (pl)
CN (1) CN113453685A (pl)
AU (1) AU2020226190A1 (pl)
CA (1) CA3129585A1 (pl)
ES (1) ES2973104T3 (pl)
HR (1) HRP20240404T1 (pl)
HU (1) HUE065972T2 (pl)
PL (1) PL3927347T3 (pl)
RS (1) RS65316B1 (pl)
WO (1) WO2020171757A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024205477A1 (en) * 2023-03-30 2024-10-03 Medivir Ab Method for treating liver cancers using fostroxacitabine bralpamide, an immune checkpoint inhibitor and a vegf antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266674A1 (en) * 2006-09-01 2010-10-21 University Of Georgia Research Foundation, Inc. L-oddc prodrugs for cancer
EA036814B9 (ru) * 2011-11-28 2021-12-27 Мерк Патент Гмбх Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение
KR102398714B1 (ko) * 2014-08-25 2022-05-17 메디비르 아베 암 치료를 위한 우리딘의 디옥솔란 유사체
WO2016162867A1 (en) * 2015-04-08 2016-10-13 Efranat Ltd. Combination therapy of macrophage activating factor and pd-1 signaling inhibitors
KR20170139110A (ko) * 2015-04-21 2017-12-18 애브비 스템센트알엑스 엘엘씨 칼리케아마이신 구성체 및 사용 방법
US10456413B2 (en) * 2016-03-02 2019-10-29 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
KR20230114331A (ko) * 2016-09-14 2023-08-01 애브비 바이오테라퓨틱스 인크. 항-pd-1 항체 및 이의 용도

Also Published As

Publication number Publication date
EP3927347A4 (en) 2022-11-16
WO2020171757A1 (en) 2020-08-27
AU2020226190A1 (en) 2021-07-15
US20220117983A1 (en) 2022-04-21
CN113453685A (zh) 2021-09-28
CA3129585A1 (en) 2020-08-27
JP2022520981A (ja) 2022-04-04
TW202045177A (zh) 2020-12-16
RS65316B1 (sr) 2024-04-30
EP3927347A1 (en) 2021-12-29
ES2973104T3 (es) 2024-06-18
EP3927347C0 (en) 2023-12-27
HUE065972T2 (hu) 2024-06-28
EP3927347B1 (en) 2023-12-27
HRP20240404T1 (hr) 2024-06-21
KR20210130768A (ko) 2021-11-01

Similar Documents

Publication Publication Date Title
IL283838A (en) A method of treating cancer by combined treatment
HK1257249A1 (zh) 使用脂質體伊立替康和parp抑制劑用於癌症治療的組合療法
IL286350A (en) Preparations and methods for the treatment of cancer
IL288914A (en) Preparations and methods for the treatment of cancer
IL276808A (en) Preparations and methods for the treatment of cancer
ZA202104870B (en) Methods and compositions for treating cancer
IL287907A (en) Cancer treatment methods
IL288086A (en) Methods and materials for cancer treatment
IL287982A (en) Preparations and methods for the treatment of cancer
IL289213A (en) A pharmaceutical preparation for tumor treatment
IL282478A (en) Materials and methods for cancer treatment
SG11202109336UA (en) Methods and compositions for treating cancer
IL280830A (en) Bracelets for use in cancer treatment methods
SG11202106295WA (en) Compositions and methods for cancer therapy
IL286153A (en) Methods and preparations for the treatment of cancer
HUE065972T2 (hu) Gyógyszerkombináció a májrák kezelésére szolgáló eljárásban történõ alkalmazásra
HK1256935A1 (zh) 使用疫苗治療癌症或皮膚病變的方法和組合物
IL286680A (en) A drug to treat cancer
EP3443090A4 (en) USE OF MIR-223-3P AS CANCER THERAPEUTIC AND METHOD FOR THE TREATMENT OF CANCER THEREWITH
IL288178A (en) Combined gmci and ddri treatment for cancer
EP4174087A4 (en) MEDICATION FOR TUMOR TREATMENT
IL285036A (en) Methods and preparations for the treatment of cancer
PT3236961T (pt) Composição farmacêutica para prevenir ou tratar cancro
EP3806905C0 (en) METHODS AND MATERIALS FOR CANCER TREATMENT
EP4069701A4 (en) COMPOSITION AND METHOD OF TREATMENT OF CANCER